Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by Leerink Partnrs

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other equities analysts have also recently issued reports on AGIO. Bank of America dropped their price target on Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright lowered their target price on Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday. Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday. Finally, The Goldman Sachs Group decreased their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $25.24 on Thursday. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $62.45. The stock has a market cap of $1.47 billion, a P/E ratio of -3.61 and a beta of 0.89. The firm has a fifty day moving average price of $39.91 and a 200 day moving average price of $36.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company had revenue of $12.90 million for the quarter, compared to analyst estimates of $10.49 million. During the same period in the previous year, the business posted $16.22 earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. Sell-side analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. This represents a 9.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 16,099 shares of company stock worth $620,092. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth $242,000. CANADA LIFE ASSURANCE Co grew its position in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 662 shares during the period. TCG Crossover Management LLC increased its holdings in Agios Pharmaceuticals by 105.2% in the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after buying an additional 733,038 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Agios Pharmaceuticals in the third quarter valued at about $5,881,000. Finally, Voleon Capital Management LP acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $268,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.